Marc Soco
@msocomd.bsky.social
🇵🇭 Internist • Nephrologist
📍 Cebu, Philippines
✈️ Balancing clinical work with a passion for travel and photography
💡 #NephJC Intern • #GlomCon Alum ‘23-24 • #NephSIM ‘20-21
📍 Cebu, Philippines
✈️ Balancing clinical work with a passion for travel and photography
💡 #NephJC Intern • #GlomCon Alum ‘23-24 • #NephSIM ‘20-21
Reposted by Marc Soco
1/10
Last #NephJC we discussed the ORIGIN 3 trial which investigated the use of Atacicept in IgAN #TenPostNephJC
Read the article 👇
www.nejm.org/doi/10....
Last #NephJC we discussed the ORIGIN 3 trial which investigated the use of Atacicept in IgAN #TenPostNephJC
Read the article 👇
www.nejm.org/doi/10....
November 20, 2025 at 12:34 AM
1/10
Last #NephJC we discussed the ORIGIN 3 trial which investigated the use of Atacicept in IgAN #TenPostNephJC
Read the article 👇
www.nejm.org/doi/10....
Last #NephJC we discussed the ORIGIN 3 trial which investigated the use of Atacicept in IgAN #TenPostNephJC
Read the article 👇
www.nejm.org/doi/10....
Reposted by Marc Soco
T4a: #NephJC
We recently got to hear the patient voice from @jonathanpollack.bsk.social
About his journey with IgAN and his excitement for a future of precision medicine while also calling for greater worldwide equity.
We recently got to hear the patient voice from @jonathanpollack.bsk.social
About his journey with IgAN and his excitement for a future of precision medicine while also calling for greater worldwide equity.
KDIGO IgA Guidelines: A Patient Voice — NephJC
We have a patient perspective on the new IgA Guidelines and what it means
to live with IgA in these times.
www.nephjc.com
November 19, 2025 at 2:52 AM
T4a: #NephJC
We recently got to hear the patient voice from @jonathanpollack.bsk.social
About his journey with IgAN and his excitement for a future of precision medicine while also calling for greater worldwide equity.
We recently got to hear the patient voice from @jonathanpollack.bsk.social
About his journey with IgAN and his excitement for a future of precision medicine while also calling for greater worldwide equity.
Reposted by Marc Soco
T3c: #NephJC
The emerging evidence from APRIL/BAFF–axis trials (including VISIONARY (sibeprenlimab) & ORIGIN-3 (atacicept)) highlight how central this pathway is to the mechanisms of IgAN.
The emerging evidence from APRIL/BAFF–axis trials (including VISIONARY (sibeprenlimab) & ORIGIN-3 (atacicept)) highlight how central this pathway is to the mechanisms of IgAN.
November 19, 2025 at 2:38 AM
T3c: #NephJC
The emerging evidence from APRIL/BAFF–axis trials (including VISIONARY (sibeprenlimab) & ORIGIN-3 (atacicept)) highlight how central this pathway is to the mechanisms of IgAN.
The emerging evidence from APRIL/BAFF–axis trials (including VISIONARY (sibeprenlimab) & ORIGIN-3 (atacicept)) highlight how central this pathway is to the mechanisms of IgAN.
Reposted by Marc Soco
Reposted by Marc Soco
Sorry will remain a dream for a while!
We may have network meta-analysis - or will have to wait for them to go generic for an NIH (if NIH will even exist) or some other public funding body to do those trials
#NephJC
We may have network meta-analysis - or will have to wait for them to go generic for an NIH (if NIH will even exist) or some other public funding body to do those trials
#NephJC
November 19, 2025 at 2:34 AM
Sorry will remain a dream for a while!
We may have network meta-analysis - or will have to wait for them to go generic for an NIH (if NIH will even exist) or some other public funding body to do those trials
#NephJC
We may have network meta-analysis - or will have to wait for them to go generic for an NIH (if NIH will even exist) or some other public funding body to do those trials
#NephJC
Reposted by Marc Soco
Same here in 🇨🇦!
Related paper: jamanetwork.com/journals/jam... in @jamainternalmed.com
Often RCTs include patients in our countries - but the pharma doesn’t bother with getting drugs approved outside the lucrative US market
#NephJC
Related paper: jamanetwork.com/journals/jam... in @jamainternalmed.com
Often RCTs include patients in our countries - but the pharma doesn’t bother with getting drugs approved outside the lucrative US market
#NephJC
Physical Accessibility of Medicines in Countries Hosting Trials for FDA Approvals
This cross-sectional study aims to determine whether and when medicines receive market authorization in the countries where they are tested for US Food and Drug Administration approval, as well as tre...
jamanetwork.com
November 19, 2025 at 2:12 AM
Same here in 🇨🇦!
Related paper: jamanetwork.com/journals/jam... in @jamainternalmed.com
Often RCTs include patients in our countries - but the pharma doesn’t bother with getting drugs approved outside the lucrative US market
#NephJC
Related paper: jamanetwork.com/journals/jam... in @jamainternalmed.com
Often RCTs include patients in our countries - but the pharma doesn’t bother with getting drugs approved outside the lucrative US market
#NephJC
Hi everyone, Marc from the Philippines.
Exciting times for IgAN… so much happening so fast! And the ASN FOMO is definitely real this year. No COI. #NephJC
Exciting times for IgAN… so much happening so fast! And the ASN FOMO is definitely real this year. No COI. #NephJC
November 19, 2025 at 2:02 AM
Hi everyone, Marc from the Philippines.
Exciting times for IgAN… so much happening so fast! And the ASN FOMO is definitely real this year. No COI. #NephJC
Exciting times for IgAN… so much happening so fast! And the ASN FOMO is definitely real this year. No COI. #NephJC
Reposted by Marc Soco
⏰ 2 hours until chat tonight
#NephJC editorial team debated for a long time...not whether to discuss @kdigo.org IgAN guidelines, but whether to do it after #Kidneywk...Have we said it well: IgAN guidelines: fresh out of press, already aging gracefully?
👀See it for yourself
#NephJC editorial team debated for a long time...not whether to discuss @kdigo.org IgAN guidelines, but whether to do it after #Kidneywk...Have we said it well: IgAN guidelines: fresh out of press, already aging gracefully?
👀See it for yourself
2025 IgAN KDIGO guidelines: fresh out of press, already aging gracefully — NephJC
This week, we will discuss the 2025 KDIGO IgAN guidelines. which the shift
from supportive care to structured, evidence-based therapy
www.nephjc.com
November 19, 2025 at 12:00 AM
⏰ 2 hours until chat tonight
#NephJC editorial team debated for a long time...not whether to discuss @kdigo.org IgAN guidelines, but whether to do it after #Kidneywk...Have we said it well: IgAN guidelines: fresh out of press, already aging gracefully?
👀See it for yourself
#NephJC editorial team debated for a long time...not whether to discuss @kdigo.org IgAN guidelines, but whether to do it after #Kidneywk...Have we said it well: IgAN guidelines: fresh out of press, already aging gracefully?
👀See it for yourself
Reposted by Marc Soco
Check out the awesome visual abstract by @salinesolut.bsky.social
Attacking the origins of IgAN with atacicept ⚔️
www.nephjc.com/news/2025/11/17/origin-3-the-visual-abstract
Attacking the origins of IgAN with atacicept ⚔️
www.nephjc.com/news/2025/11/17/origin-3-the-visual-abstract
ORIGIN-3: The Visual Abstract — NephJC
Atacicept, BAFF/APRIL inhibition in IgAN
www.nephjc.com
November 18, 2025 at 12:32 PM
Check out the awesome visual abstract by @salinesolut.bsky.social
Attacking the origins of IgAN with atacicept ⚔️
www.nephjc.com/news/2025/11/17/origin-3-the-visual-abstract
Attacking the origins of IgAN with atacicept ⚔️
www.nephjc.com/news/2025/11/17/origin-3-the-visual-abstract
Reposted by Marc Soco
Resuman Visual
Revisa el resumen visual realizado por Clemens Weber @salinesolut.bsky.social . Gracias @dramiliflores.bsky.social !
www.nephjc.com/news/2025/11/17/origin-3-el-resumen-visual
Revisa el resumen visual realizado por Clemens Weber @salinesolut.bsky.social . Gracias @dramiliflores.bsky.social !
www.nephjc.com/news/2025/11/17/origin-3-el-resumen-visual
ORIGIN-3: El Resumen Visual — NephJC
ORIGIN-3 ha llegado a NephJC con atacicept en NIgA. Un paso sólido hacia una terapia dirigida anti BAFF/APRIL, que aborda la fisiopatología desde su origen. ¡Las señales tempranas son prometedoras! R...
www.nephjc.com
November 18, 2025 at 12:38 PM
Resuman Visual
Revisa el resumen visual realizado por Clemens Weber @salinesolut.bsky.social . Gracias @dramiliflores.bsky.social !
www.nephjc.com/news/2025/11/17/origin-3-el-resumen-visual
Revisa el resumen visual realizado por Clemens Weber @salinesolut.bsky.social . Gracias @dramiliflores.bsky.social !
www.nephjc.com/news/2025/11/17/origin-3-el-resumen-visual
Reposted by Marc Soco
Tonite 11/18/25 on #Bluesky 9pm EST
We are discussing ORIGIN3 and atacicept in IgAN.
APRIL, BAFF and B-cells, Oh My! (🦁🐯🐻)
It's going to be Wicked good. 🧙♀️ #NephJC
Summary by @notjustdialysis.bsky.social
www.nephjc.com/news/atacicept-origin3-gtfb36
We are discussing ORIGIN3 and atacicept in IgAN.
APRIL, BAFF and B-cells, Oh My! (🦁🐯🐻)
It's going to be Wicked good. 🧙♀️ #NephJC
Summary by @notjustdialysis.bsky.social
www.nephjc.com/news/atacicept-origin3-gtfb36
Attacking the Origin of IgAN: ORIGIN3 and Atacicept — NephJC
This week, we will discuss the phase 3 ORIGIN3 trial of atacicept, an APRIL/BAFF inhibitor for use in IgAN.
www.nephjc.com
November 18, 2025 at 12:29 PM
Tonite 11/18/25 on #Bluesky 9pm EST
We are discussing ORIGIN3 and atacicept in IgAN.
APRIL, BAFF and B-cells, Oh My! (🦁🐯🐻)
It's going to be Wicked good. 🧙♀️ #NephJC
Summary by @notjustdialysis.bsky.social
www.nephjc.com/news/atacicept-origin3-gtfb36
We are discussing ORIGIN3 and atacicept in IgAN.
APRIL, BAFF and B-cells, Oh My! (🦁🐯🐻)
It's going to be Wicked good. 🧙♀️ #NephJC
Summary by @notjustdialysis.bsky.social
www.nephjc.com/news/atacicept-origin3-gtfb36
Reposted by Marc Soco
We had a lot of discussion with Barratt at his rounds on this.
His point is that
- early diagnosis/identification early in disease process will be key
- we do have specific treatment options available now (or will soon have)
- just RASi and Flozins without biopsy just masks the issue
#NephJC
His point is that
- early diagnosis/identification early in disease process will be key
- we do have specific treatment options available now (or will soon have)
- just RASi and Flozins without biopsy just masks the issue
#NephJC
October 29, 2025 at 1:25 AM
We had a lot of discussion with Barratt at his rounds on this.
His point is that
- early diagnosis/identification early in disease process will be key
- we do have specific treatment options available now (or will soon have)
- just RASi and Flozins without biopsy just masks the issue
#NephJC
His point is that
- early diagnosis/identification early in disease process will be key
- we do have specific treatment options available now (or will soon have)
- just RASi and Flozins without biopsy just masks the issue
#NephJC
Reposted by Marc Soco
🎨Beautiful visual abstract by Dr Natalia Nombera @roxnonna23.bsky.social #NephJC
www.nephjc.com/news/...
www.nephjc.com/news/...
October 29, 2025 at 1:04 AM
🎨Beautiful visual abstract by Dr Natalia Nombera @roxnonna23.bsky.social #NephJC
www.nephjc.com/news/...
www.nephjc.com/news/...
Reposted by Marc Soco
🔬for the diagnosis of glowmrulonephritis, searching for urinary acanthocytes only using bright field illumination is clearly suboptimal compared to utilizing dark field illumination or phase contrast microscopy. #UrinarySediment #UrineMicroscopy karger.com/gdz/article/...
October 25, 2025 at 12:31 AM
🔬for the diagnosis of glowmrulonephritis, searching for urinary acanthocytes only using bright field illumination is clearly suboptimal compared to utilizing dark field illumination or phase contrast microscopy. #UrinarySediment #UrineMicroscopy karger.com/gdz/article/...
Reposted by Marc Soco
⏩ Next #NephJC is on IgA nephropathy @kdigo.org guideline
🎨 Nice visual summary by @roxnonna23.bsky.social
www.nephjc.com/news/2025/10...
🎨 Nice visual summary by @roxnonna23.bsky.social
www.nephjc.com/news/2025/10...
KDIGO 2025 IgA guidelines - Visual Abstract — NephJC
KDIGO 2025 is here. IgAN management is evolving with precision risk tools, new therapies, and a stronger focus on kidney protection. Check out the visual abstract created by Natalia Nombera
www.nephjc.com
October 27, 2025 at 5:27 PM
⏩ Next #NephJC is on IgA nephropathy @kdigo.org guideline
🎨 Nice visual summary by @roxnonna23.bsky.social
www.nephjc.com/news/2025/10...
🎨 Nice visual summary by @roxnonna23.bsky.social
www.nephjc.com/news/2025/10...
Reposted by Marc Soco
Obinituzumab aka ‘Obi’ is now FDA approved for lupus nephritis
finance.yahoo.com/news/fda-app...
#lupus
finance.yahoo.com/news/fda-app...
#lupus
FDA Approves Genentech’s Gazyva for the Treatment of Lupus Nephritis
SOUTH SAN FRANCISCO, Calif., October 20, 2025--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Gazyva...
finance.yahoo.com
October 20, 2025 at 11:14 AM
Obinituzumab aka ‘Obi’ is now FDA approved for lupus nephritis
finance.yahoo.com/news/fda-app...
#lupus
finance.yahoo.com/news/fda-app...
#lupus
Reposted by Marc Soco
🎨Beautiful visual abstract by @msocomd.bsky.social #NephJC
Protein supplementation in CKD: The Visual Abstract — NephJC
We like protein, or do we? Low protein, high protein, supplements…what’s a
nephrologist to do?
www.nephjc.com
October 15, 2025 at 1:06 AM
🎨Beautiful visual abstract by @msocomd.bsky.social #NephJC
Reposted by Marc Soco
Check the insightful #NephJC summary by @shelliefravel.bsky.social
The Protein Pendulum in CKD: supplement or restrict? — NephJC
This week, we will discuss an old dilemma in nephrology. To restrict or
supplement the proteins? Premise: advanced CKD and dialysis.
www.nephjc.com
October 15, 2025 at 1:05 AM
Check the insightful #NephJC summary by @shelliefravel.bsky.social
Reposted by Marc Soco
Check at the VA for our discussion of protein diet strategies by @msocomd.bsky.social. Is restricting protein in CKD and pushing protein in ESRD #TWDFNR?
www.nephjc.com/news/2025/10...
www.nephjc.com/news/2025/10...
Protein supplementation in CKD: The Visual Abstract — NephJC
We like protein, or do we? Low protein, high protein, supplements…what’s a nephrologist to do?
www.nephjc.com
October 13, 2025 at 1:14 PM
Check at the VA for our discussion of protein diet strategies by @msocomd.bsky.social. Is restricting protein in CKD and pushing protein in ESRD #TWDFNR?
www.nephjc.com/news/2025/10...
www.nephjc.com/news/2025/10...